JP2019516394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516394A5 JP2019516394A5 JP2019500712A JP2019500712A JP2019516394A5 JP 2019516394 A5 JP2019516394 A5 JP 2019516394A5 JP 2019500712 A JP2019500712 A JP 2019500712A JP 2019500712 A JP2019500712 A JP 2019500712A JP 2019516394 A5 JP2019516394 A5 JP 2019516394A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- seq
- pharmaceutical composition
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 17
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000007935 neutral effect Effects 0.000 claims 8
- 230000002378 acidificating effect Effects 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 238000001727 in vivo Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 101100450694 Arabidopsis thaliana HFR1 gene Proteins 0.000 claims 2
- 238000013096 assay test Methods 0.000 claims 2
- 231100000628 reference dose Toxicity 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000002638 palliative care Methods 0.000 claims 1
- 238000011499 palliative surgery Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022008113A JP7345578B2 (ja) | 2016-03-23 | 2022-01-21 | 新規抗ｐｄ－ｌ１抗体 |
| JP2023143484A JP7624484B2 (ja) | 2016-03-23 | 2023-09-05 | 新規抗ｐｄ－ｌ１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/077082 | 2016-03-23 | ||
| CN2016077082 | 2016-03-23 | ||
| PCT/CN2017/073242 WO2017161976A1 (en) | 2016-03-23 | 2017-02-10 | Novel anti-pd-l1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022008113A Division JP7345578B2 (ja) | 2016-03-23 | 2022-01-21 | 新規抗ｐｄ－ｌ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516394A JP2019516394A (ja) | 2019-06-20 |
| JP2019516394A5 true JP2019516394A5 (enExample) | 2020-03-19 |
| JP7080213B2 JP7080213B2 (ja) | 2022-06-03 |
Family
ID=59900827
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500712A Active JP7080213B2 (ja) | 2016-03-23 | 2017-02-10 | 新規抗ｐｄ－ｌ１抗体 |
| JP2022008113A Active JP7345578B2 (ja) | 2016-03-23 | 2022-01-21 | 新規抗ｐｄ－ｌ１抗体 |
| JP2023143484A Active JP7624484B2 (ja) | 2016-03-23 | 2023-09-05 | 新規抗ｐｄ－ｌ１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022008113A Active JP7345578B2 (ja) | 2016-03-23 | 2022-01-21 | 新規抗ｐｄ－ｌ１抗体 |
| JP2023143484A Active JP7624484B2 (ja) | 2016-03-23 | 2023-09-05 | 新規抗ｐｄ－ｌ１抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10822416B2 (enExample) |
| EP (1) | EP3433277A4 (enExample) |
| JP (3) | JP7080213B2 (enExample) |
| KR (1) | KR20180127971A (enExample) |
| CN (2) | CN108779180B (enExample) |
| CA (1) | CA3007135A1 (enExample) |
| RU (1) | RU2744959C2 (enExample) |
| WO (1) | WO2017161976A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106243225B (zh) * | 2015-06-11 | 2021-01-19 | 智翔（上海）医药科技有限公司 | 新型抗-pd-l1抗体 |
| EP3433277A4 (en) * | 2016-03-23 | 2020-06-17 | Mabspace Biosciences (Suzhou) Co., Ltd | NEW ANTI-PD-L1 ANTIBODIES |
| CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| JP7021454B2 (ja) * | 2017-02-03 | 2022-02-17 | 株式会社三洋物産 | 遊技機 |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| WO2019108755A1 (en) * | 2017-11-30 | 2019-06-06 | Genentech, Inc. | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
| CN115925943A (zh) * | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CN111542543B (zh) * | 2017-12-28 | 2023-12-22 | 南京传奇生物科技有限公司 | 针对pd-l1的抗体及其变体 |
| AU2019275737A1 (en) | 2018-06-01 | 2021-01-21 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| AU2019293047A1 (en) | 2018-06-29 | 2021-01-28 | Gensun Biopharma Inc. | Antitumor immune checkpoint regulator antagonists |
| US20210147549A1 (en) * | 2018-07-11 | 2021-05-20 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1 |
| US12263234B2 (en) * | 2019-01-23 | 2025-04-01 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-PD-L1 diabodies and the use thereof |
| WO2020151759A1 (zh) | 2019-01-25 | 2020-07-30 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| EP3976090A1 (en) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| CN114127315A (zh) * | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| CN110194798A (zh) * | 2019-05-31 | 2019-09-03 | 杭州科兴生物科技有限公司 | 抗pd-l1单克隆抗体、片段及其医药用途 |
| EP3990116A1 (en) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| GB201910138D0 (en) * | 2019-07-15 | 2019-08-28 | Capella Bioscience Ltd | Anti-pd-l1 antibodies |
| CA3157516A1 (en) * | 2019-11-08 | 2021-05-14 | Xinyan Zhao | Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof |
| WO2021197358A1 (zh) * | 2020-03-31 | 2021-10-07 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1和pd-l2抗体及其衍生物和用途 |
| WO2022022503A1 (en) * | 2020-07-28 | 2022-02-03 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting pd-l1 and tgf-beta |
| EP4192884A4 (en) * | 2020-08-04 | 2025-04-09 | Exelixis, Inc. | PD-L1-BINDING AGENTS AND USES THEREOF |
| CN111929447B (zh) * | 2020-09-24 | 2021-02-26 | 菁良基因科技(深圳)有限公司 | 一种pd-l1免疫组织化学参考品及其制备方法和应用 |
| KR20230110546A (ko) * | 2020-11-18 | 2023-07-24 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | 이작용성 분자 |
| CN112285366B (zh) * | 2020-12-25 | 2021-06-08 | 南京广祺医药科技有限公司 | 一种测定血清中双特异性抗体BsAb的ELISA方法及应用 |
| WO2023001987A2 (en) | 2021-07-22 | 2023-01-26 | University Of Dundee | Therapeutic muteins |
| CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
| US20240382411A1 (en) * | 2021-09-18 | 2024-11-21 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Composition comprising pd-l1 antigen-binding fragment and use thereof |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| TW202333785A (zh) * | 2021-11-16 | 2023-09-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | Ｃｌａｕｄｉｎ１８．２拮抗劑和ｐｄ－１／ｐｄ－ｌ１軸抑制劑的組合療法 |
| WO2023221936A1 (zh) | 2022-05-17 | 2023-11-23 | 苏州创胜医药集团有限公司 | 双功能蛋白质及其制剂和用途 |
| CN114939161B (zh) * | 2022-06-24 | 2023-02-28 | 南方医科大学南方医院 | Pd-1抗体在制备治疗肌腱损伤的药物中的应用 |
| KR20250139314A (ko) * | 2023-01-18 | 2025-09-23 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 안티-pdl1 단일 도메인 항체, 융합 단백질 및 이의 용도 |
| AU2024269754A1 (en) * | 2023-05-08 | 2025-10-23 | F. Hoffmann-La Roche Ag | Targeted interferon alpha fusion proteins and methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| HRP20151102T1 (xx) * | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| US8217849B2 (en) | 2008-04-07 | 2012-07-10 | Intelleflex Corporation | Small profile antenna and RFID device having same |
| KR20250091300A (ko) * | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP5844159B2 (ja) * | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| RU2416645C2 (ru) * | 2009-05-04 | 2011-04-20 | Общество с ограниченной ответственностью "Промоген-МАТ" | Одноцепочечное антитело, связывающее фактор некроза опухоли альфа, днк, плазмидная днк и способ получения одноцепочечного антитела |
| DK2504364T3 (da) | 2009-11-24 | 2017-11-06 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| KR102541217B1 (ko) * | 2011-10-10 | 2023-06-08 | 시티 오브 호프 | 메디토프와 메디토프-결합 항체 및 이들의 용도 |
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| SG10201700698WA (en) * | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2013181634A2 (en) | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| US9828434B2 (en) * | 2012-10-04 | 2017-11-28 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-PD-L1 antibodies and methods of use |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014165082A2 (en) * | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
| KR102389677B1 (ko) * | 2013-03-15 | 2022-04-21 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| EP3433277A4 (en) * | 2016-03-23 | 2020-06-17 | Mabspace Biosciences (Suzhou) Co., Ltd | NEW ANTI-PD-L1 ANTIBODIES |
-
2017
- 2017-02-10 EP EP17769253.0A patent/EP3433277A4/en active Pending
- 2017-02-10 JP JP2019500712A patent/JP7080213B2/ja active Active
- 2017-02-10 CA CA3007135A patent/CA3007135A1/en active Pending
- 2017-02-10 WO PCT/CN2017/073242 patent/WO2017161976A1/en not_active Ceased
- 2017-02-10 RU RU2018124602A patent/RU2744959C2/ru active
- 2017-02-10 KR KR1020187024767A patent/KR20180127971A/ko active Pending
- 2017-02-10 CN CN201780018886.4A patent/CN108779180B/zh active Active
- 2017-02-10 CN CN202010174431.5A patent/CN111363041B/zh active Active
- 2017-02-10 US US16/086,013 patent/US10822416B2/en active Active
-
2020
- 2020-09-28 US US17/033,970 patent/US11753473B2/en active Active
-
2022
- 2022-01-21 JP JP2022008113A patent/JP7345578B2/ja active Active
-
2023
- 2023-09-05 JP JP2023143484A patent/JP7624484B2/ja active Active